Optimi Health Corp.

F-1/A amended

Optimi Health Corp. is conducting an initial public offering (IPO) of 2,500,000 common shares in the U.S., with an expected price range of $6.00 to $8.00 per share. The offering includes underwriter warrants and potential additional shares via an over-allotment option. The company, a Canadian pharmaceutical manufacturer of controlled substances like MDMA and psilocybin, seeks to list on Nasdaq under the symbol "OPTH." A reverse share split (1-for-30) is planned to meet Nasdaq's minimum share price requirement. The company is subject to stringent regulatory frameworks in multiple jurisdictions and faces risks related to legal uncertainties around psychedelic drugs.

F-1/A amended

Optimi Health Corp. filed an amended F-1/A registration statement for its U.S. IPO, detailing an offering of 2,142,857 common shares at an expected price range of $6.00 to $8.00 per share. The filing includes a reverse share split (1-for-30) to meet Nasdaq listing requirements and outlines plans to list on Nasdaq under the symbol 'OPTH'. The company, a Canadian GMP-compliant pharmaceutical manufacturer of psychedelics, highlights its regulatory licenses for controlled substances and ongoing clinical trials for MDMA and psilocybin in Canada and Australia. The filing also notes the underwriter's option to purchase additional shares and updated financial disclosures.

F-1/A amended

Optimi Health Corp. is conducting an initial public offering (IPO) of common shares in the U.S., with an aggregate offering size yet to be specified. The company, licensed by Health Canada for controlled substances and GMP-compliant pharmaceutical production, focuses on psychedelics like MDMA and psilocybin. The filing includes details on underwriter warrants, a reverse share split, and plans to list on Nasdaq. The company emphasizes its regulatory compliance and expansion into markets where psychedelics are legal for therapeutic use, while highlighting risks related to U.S. Schedule I classifications and regulatory approvals.

F-1 filed

Optimi Health Corp. is conducting an initial public offering (IPO) of common shares in the U.S., with an aggregate offering size yet to be specified. The company, a Canadian GMP-compliant pharmaceutical manufacturer specializing in controlled substances like MDMA and psilocybin, is seeking to list on Nasdaq after a reverse share split to meet minimum share price requirements. It operates under Health Canada licenses, enabling regulated sales in Canada, Australia, and through clinical trials in other jurisdictions. The filing highlights its unique position as a supplier of prescription psychedelics in certain markets, alongside risks related to U.S. regulatory restrictions and reliance on regulatory approvals.

DRS/A amended

Optimi Health Corp. is conducting an initial public offering (IPO) of common shares in the U.S., with an anticipated price range of US$ to US$ per share. The company, a Canadian GMP-compliant pharmaceutical manufacturer, specializes in controlled substances like MDMA and psilocybin. The filing includes details about a reverse share split, Nasdaq listing application, and underwriter options. The company operates under a Drug Establishment Licence (DEL) and Dealer’s Licence (DL) in Canada, enabling regulated sales in Australia and other markets. The offering is subject to regulatory approvals and market conditions.

DRS filed

Optimi Health Corp. is conducting an initial public offering (IPO) of common shares in the U.S., aiming to list on the Nasdaq Capital Market under the symbol 'OPTH.' The company specializes in manufacturing controlled substances MDMA and psilocybin, with GMP-certified facilities and regulatory approvals in Canada. The offering includes common shares, underwriter warrants, and potential additional shares via an over-allotment option. The company is an emerging growth company and a foreign private issuer, with a reverse share split pending Nasdaq approval. The filing is confidential and not yet effective.